Lung Cancer Metastatic Clinical Trials

9 recruiting

Lung Cancer Metastatic Trials at a Glance

16 actively recruiting trials for lung cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in San Francisco, Shanghai, and Guangzhou. Lead sponsors running lung cancer metastatic studies include Sun Yat-sen University, Collin Blakely, and Centre hospitalier de l'Université de Montréal (CHUM).

Browse lung cancer metastatic trials by phase

Treatments under study

About Lung Cancer Metastatic Clinical Trials

Looking for clinical trials for Lung Cancer Metastatic? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Lung CancerBrain MetastasesLung Cancer Metastatic
University of California, Davis20 enrolled1 locationNCT05452005
Recruiting
Phase 2

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Lung CancerBrain Metastases, AdultBrain Metastases+1 more
Memorial Sloan Kettering Cancer Center62 enrolled7 locationsNCT05419076
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Not Applicable

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

Non-small Cell Lung Cancer Metastatic
Zealand University Hospital350 enrolled5 locationsNCT05889247
Recruiting
Not Applicable

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

Lung CancerLung NeoplasmsLung Cancer Metastatic+2 more
RenJi Hospital100 enrolled1 locationNCT07026110
Recruiting
Phase 3

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Head and Neck CancerRenal Cell CarcinomaLung Cancer Metastatic
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIMetastatic Non-small Cell Lung Cancer (NSCLC)
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting
Phase 2

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Non-small Cell Lung Cancer Metastatic
Sun Yat-sen University30 enrolled1 locationNCT06812871
Recruiting
Phase 1Phase 2

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Lung CancerLung Cancer Metastatic
Essen Biotech85 enrolled1 locationNCT06538012
Recruiting

Primary Tumor Resection for M1a Stage Lung Cancer

Lung Cancer MetastaticSurgical Resection
Fudan University66 enrolled1 locationNCT06547710
Recruiting
Phase 2

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Phase 1

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer MetastaticEGFR Gene Mutation
Collin Blakely38 enrolled1 locationNCT04085315
Recruiting
Phase 1

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Non-small Cell Lung Cancer Metastatic
Lu Shun35 enrolled1 locationNCT06083870
Recruiting
Phase 2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Lung Cancer Metastatic
Centre hospitalier de l'Université de Montréal (CHUM)68 enrolled1 locationNCT04405401
Recruiting
Phase 3

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic
Shanghai Cancer Hospital, China300 enrolled1 locationNCT05800223